Published in final edited form as:

J Org Chem. 2009 January 16; 74(2): 782–788. doi:10.1021/jo802410u.

Reactions of *N*-Benzyloxycarbamate Derivatives with Stabilized Carbon Nucleophiles-A New Synthetic Approach to Polyhydroxamic Acids and Other Hydroxamate Containing Mixed Ligand Systems

Yuan Liu, Hollie K. Jacobs, and Aravamudan S. Gopalan*

Department of Chemistry and Biochemistry, MSC 3C, New Mexico State University, Las Cruces, NM 88003-8001

Abstract

Hydroxamic acids are an important class of chelators of hard metal ions such as Fe(III), which have found applications in therapeutic, diagnostic and separation chemistry. Hence, methods for their preparation and incorporation into various matrices are important. A new strategy for the preparation of hydroxamic acids that uses readily available *N*-benzyloxy carbamic acid ethyl ester, **1**, has been developed. *N*-Alkylation of **1** occurs readily to give *N*-alkyl-*N*-benzyloxy carbamates, **2**, which react with a variety of stabilized carbon nucleophiles to give functionalized protected hydroxamic acids, **3**, in good to excellent yields. The *O*-protected hydroxamate intermediates **3** can be further alkylated with halides to access a variety of potential metal binding hosts. The usefulness of this methodology has been demonstrated by the synthesis of a novel trihydroxamic acid **6**, mixed ligand systems, **9** and **12**, and the macrocyclic dihydroxamic acid **16**.

Introduction

Hydroxamic acids are well-known chelators of hard metal ions such as Fe(III) and the actinide (IV) ions. Many bacterial and fungal siderophores rely on the hydroxamate functionality to complex and transport the ferric ion.¹ Desferrioxamine, a trihydroxamate siderophore, is used for the treatment of iron overload in patients with β -thalassemia.² Recently, hydroxamic acid iron chelators have been examined as potential cancer chemotherapeutic agents.³ Another potential application of iron chelators is in the development of novel anti-bacterial agents.⁴ In addition to their role as iron chelators, hydroxamic acids exhibit varied biological activity including antibacterial, antifungal, anti-inflammatory and antitumor properties, which are due to their ability to inhibit a variety of enzymes.⁵ There has been a recent surge in the interest of hydroxamic acids as inhibitors of histone deacetylases resulting in the recent approval of suberoylanilide hydroxamic acid (SAHA) for the treatment of cutaneous T-cell lymphoma.⁶ It is also noteworthy that many hydroxamic acid containing molecules are potent inhibitors of

matrix metalloproteinases, which have been implicated in a number of pathological conditions.⁷ Given the incredible pharmaceutical relevance of hydroxamic acids⁸, it is essential to develop new methods for their incorporation into a variety of complex structures.

As part of a program for the design and synthesis of chelators for the specific binding of ferric ion, we have been interested in developing methods for the preparation of a variety of hydroxamic acids including polyhydroxamic acids.⁹ The conventional method for the preparation of hydroxamic acids usually involves coupling of acid derivatives with hydroxylamines.^{10, 11} Recently, there has been considerable interest in parallel methods for the synthesis of hydroxamic acids both in solution and on solid support.¹² The microwave-assisted conversion of esters into hydroxamic acids was recently reported.¹³ However, the limited availability of substituted hydroxylamines places limits on the traditional coupling method, in particular in terms of the diversity of polyhydroxamates and mixed hydroxamate ligand systems that can be readily accessed.

The direct reaction of *N*-benzyloxy carbamates, such as **2**, with carbon nucleophiles is an attractive alternate approach for the synthesis of hydroxamic acids (Figure 1). There may be a couple of reasons that this strategy has not been explored. Carbamates are usually viewed as useful amine protecting groups and not as efficient electrophiles. Only recently, it was reported that simple carbamates can act as electrophiles when reacted with the dianion of methyl phenyl sulfone to give amidosulfones.¹⁴ It has also been shown that α -sulfonyl carbanions undergo intramolecular cyclization with carbamates to yield lactams.¹⁵

Another reason carbamates, such as **2**, have not been thought to be good synthons for the preparation of hydroxamic acids may be a perceived similarity to the well-known Weinreb amide chemistry. Reaction of **2** with a strongly basic nucleophile such as *n*-butyl lithium would be expected to give an intermediate Weinreb-like amide, **I**, that would react further to give the corresponding ketone (Figure 1). As predicted, when **2** was treated with *n*-butyllithium (2 eq), 5-nonanone was obtained in high yield.¹⁶

However, we postulated that reaction of an *N*-benzyloxy carbamate, such as **2**, with stabilized carbanions should circumvent this reaction pathway and lead to the desired hydroxamate product **3** (Figure 1). Intermediate **II**, obtained by the reaction of **2** when a stabilized carbanion serves as the nucleophile, has an acidic proton and will be expected to undergo immediate deprotonation to give a stable carbanion **III**, incapable of functioning as an electrophile. Here we report a novel preparation of hydroxamic acids based on our hypothesis that allows us to access a variety of hydroxamic acids and mixed ligand chelators.

Results and Discussion

The *N*-benzyloxycarbamate **1** was prepared by the reaction of *O*-benzylhydroxylamine hydrochloride with ethyl chloroformate in pyridine at room temperature in excellent yield (Scheme 1). It is important to point out that the use of triethylamine or 4-methylmorpholine instead of pyridine in this reaction gave mixtures of the desired product **1** along with major quantities of the corresponding *N,N*-diacylated product.

A number of *N*-alkylcarbamates were readily prepared by alkylation of **1** using one of two conditions (Scheme 1). For example, treatment of **1** with NaH in DMF followed by addition of methyl iodide (1.1 eq.) gave **2a** in 93% yield. *N*-Benzyl carbamate, **2c**, potentially a convenient synthon for the synthesis of primary hydroxamic acids, was prepared using a similar procedure. The dicarbamate **2d** could be prepared in excellent yields by alkylation of **1** with dibromopentane (0.5 eq.) in the presence of K₂CO₃ in refluxing acetonitrile.

With the *N*-benzyloxycarbamates **2** in hand, their reactions with stabilized carbon nucleophiles were then examined. The carbamate **2a** served as the model in our initial studies. Treatment of methyl phenyl sulfone (1 eq) with LHMDs (2 eq) in THF at -78°C followed by addition of *N*-benzyloxycarbamate **2a** (1 eq) gave the corresponding protected hydroxamic acid **3a** in 72% yield after work up and chromatographic purification. It was gratifying to note that our key postulate in the development of this methodology proved to be right. The presence of the electron withdrawing sulfone group on the carbon nucleophile clearly suppresses the undesired Weinreb chemistry of the initial intermediate **II** and promotes rapid proton abstraction of the intermediate to give an enolate **III** as illustrated in Figure 1.

The coupling reaction proved to be quite general and a variety of stabilized carbon nucleophiles could be coupled with **2a** and its analogs to give the corresponding functionalized protected hydroxamic acids, **3**, in good to excellent yield (see Table 1). In most cases, efficient coupling of **2** to give **3** could be achieved by use of only 1 equivalent of the carbon nucleophile and two equivalents of LHMDs. Carbon nucleophiles carrying sulfoxide, phosphonate, sulfonamide, ester and nitrile moieties all reacted successfully with **2** to give the corresponding product **3** in good to excellent yields. When the enolate of *t*-butyl acetate was used in the reaction with **2** under the standard conditions, the yields were somewhat lower due to competing self-condensation of the ester.¹⁷ Hence, 2 equivalents of the ester enolate were initially generated with LHMDs and subsequent coupling with **2** gave good yields of the desired product. The anions of ethyl phenyl sulfone and allyl phenyl sulfone reacted cleanly with **2a** to give the desired products **3g** and **3h** in 92 and 79% yields, respectively. Further, it was possible to acylate the dicarbamate **2d** with carbon nucleophiles of interest to give products **3k–3m** in good yields. One reaction that did fail was the attempted acylation of the enolate of *t*-butyl propionate with carbamate **2a** presumably due to unfavorable steric factors and competing side reactions.

The presence of electron withdrawing groups on the *N*-benzyloxy hydroxamates **3**, allow further synthetic manipulations to obtain other polydentate chelators. The synthetic utility of these intermediates has been demonstrated by the synthesis of a number of metal ion binding hosts. The first target to be synthesized was the trihydroxamic acid **6**, a potential iron chelator (Scheme 2). Treatment of 1,3,5-tris(bromomethyl)benzene with 3 equivalents of **3e** in the presence of potassium carbonate in refluxing acetonitrile gave the desired product of trialkylation, **4**, in 72% yield after chromatographic purification. Hydrolysis of the *t*-butyl esters by treatment with trifluoroacetic acid in dichloromethane and subsequent decarboxylation of the intermediate acid in refluxing toluene gave **5**. The benzyl protecting groups of **5** were removed using 10% Pd/C to give the trihydroxamic acid **6** in 71% yield.¹⁸ It is interesting to note that the trihydroxamic acid **6** is not only soluble in organic solvents but also in water.

It was felt that the dihydroxamate *t*-butyl ester **3k** and the dihydroxamate sulfone **3l** were both good platforms that would allow the introduction of a variety of other ligands to obtain novel classes of metal ion chelators. To demonstrate this possibility we embarked on the synthesis of dihydroxamic acid polyether **9** (Scheme 3) from the *t*-butyl ester **3k**. When **3k** was treated with allyl bromide (6 eq) in the presence of potassium carbonate in refluxing acetonitrile, the corresponding diallyl dihydroxamic acid could be isolated in 80% yield. Unfortunately, our attempts to introduce a polyether side chain by alkylation of **3k** with the less reactive 1-iodo-2-(2-methoxy-ethoxy)-ethane failed and only unreacted starting materials were recovered. This forced us to examine the use of the disulfone **3l** in this synthesis.

Treatment of disulfone **3l** with 2.3 equivalents of 1-iodo-2-(2-methoxyethoxy)ethane and potassium carbonate in refluxing acetonitrile gave the dialkylated product **7** in 82% yield after purification (Scheme 3). Subsequent desulfonation using 6% Na/Hg amalgam followed by

removal of the benzyl protecting groups by hydrogenolysis gave the desired dihydroxamic acid **9**. The presence of two hydroxamic acids as well as two polyether arms makes **9** a unique metal ion binding ligand.

Two important classes of chelators for hard trivalent and tetravalent cations contain the bidentate hydroxamic acids or hydroxypyridinone ligands in their backbones. We have used the disulfone **3l** to construct a unique mixed ligand chelator **12** having both 3,2-hydroxypyridinone (HOPO) and hydroxamic acid ligands (Scheme 4). Alkylation of **3l** with 2.4 equivalents of the hydroxypyridinone iodide **13**¹⁹ using potassium carbonate in refluxing acetonitrile gave the desired product **10** in 89% yield after purification. Reductive removal of the sulfone followed by benzyl deprotection by hydrogenolysis gave the dihydroxamic acid/diHOPO ligand **12**. This interesting ligand may be well-suited to bind hard cations like Pu(IV) and Th(IV) which have larger coordination number than iron(III).²⁰

The diene intermediate **3m** provides a pathway to access macrocyclic dihydroxamic acids by RCM exemplified by our synthesis of **16**. When the diene **3m** was treated with 5 mol% Grubbs' II catalyst in refluxing dichloromethane the cyclic product **14** was obtained in 85% yield after purification (Scheme 5). The macrocycle **14** was obtained as a diastereomeric mixture as determined by ¹H NMR. The sulfone groups were removed using 6% Na/Hg amalgam. Finally, hydrogenolysis of the benzyl protecting groups with concomitant reduction of the double bond gave the desired dihydroxamic acid **16**. Macrocyclic dihydroxamic acids, such as the siderophores bisucaberin and alcaligin, have been shown to bind Fe(III) strongly. Macrocyclic hydroxamic acids have also been shown to be inhibitors of MMPs²¹ and TACE.²²

In summary, *N*-benzyloxycarbamic acid ethyl ester, **1**, is a useful starting material for the preparation of *N*-alkyl carbamates **2** that serve as synthons for the preparation of hydroxamic acids. We have demonstrated that carbon nucleophiles stabilized by a variety of electron withdrawing groups react with carbamates, **2**, to give functionalized protected hydroxamic acids, **3**. As hypothesized, the use of stabilized carbon nucleophiles in the reaction with **2** yields the enolate of the initially formed coupled product, suppressing the Weinreb chemistry. The intermediates **3** obtained in this study can be elaborated by subsequent reactions to incorporate other desirable ligand moieties or can be easily incorporated into diverse spacer groups. Finally, we have demonstrated that this new methodology can be used to prepare a variety of polyhydroxamic acids including mixed ligand HOPO-hydroxamate ligand systems and cyclic dihydroxamic acids. We are confident that the electrophilic chemistry of *N*-benzyloxy carbamates will lead to a range of new interesting applications.

Experimental Section

N-Benzyloxycarbamic acid ethyl ester (**1**)

A mixture of *O*-benzylhydroxylamine hydrochloride (1.59 g, 10 mmol) and pyridine (5 mL) was stirred at rt under N₂ for 2 h. The mixture was then cooled to 0°C, and ethyl chloroformate (0.96 mL, 10 mmol) was added and the mixture was stirred at rt for 16 h. The reaction mixture was diluted with EtOAc (100 mL), washed with 2*N* HCl (3×30 mL), sat'd NaHCO₃ (3×30 mL), and dried (Na₂SO₄). The solvent was removed *in vacuo*. The carbamate **1** (1.84 g, 94.6%) was obtained as a colorless oil which was homogeneous by TLC and was used in the next step without purification: IR (neat) 3277, 2983, 1724 cm⁻¹; ¹H NMR (400 MHz) δ 7.91(s, 1H), 7.37-7.29(m, 5H), 4.81(s, 2H), 4.14(q, *J*=7.2 Hz, 2H), 1.22(t, *J*=7.2 Hz, 3H); ¹³C NMR (100 MHz) δ 157.8, 135.6, 129.1, 128.5, 128.4, 78.5, 61.8, 14.4. Anal. Calcd for C₁₀H₁₃NO₃: C, 61.53; H, 6.71; N, 7.18. Found: C, 61.20; H, 6.63; N, 7.24.

N-Benzyloxy-N-methylcarbamic acid ethyl ester (2a)

Sodium hydride (60% mineral oil dispersion, 0.408 g, 10.2 mmol) was added to a solution of **1** (1.80 g, 9.2 mmol) in dry DMF (10 mL) at rt. After 30 min, iodomethane (0.65 mL, 10.2 mmol) was added and the mixture was stirred at rt for 6 h. The reaction mixture was poured into water (150 mL), and the product extracted into hexane (3×50 mL). The combined organic layer was dried (Na₂SO₄) and the solvent was removed *in vacuo*. Purification by flash chromatography gave **2a**²³ (1.55 g, 80.6%) as colorless oil: ¹H NMR (200 MHz, CDCl₃) δ 7.52–7.29(m, 5H), 4.86(s, 1H), 4.21(q, *J*=7.0 Hz, 1H), 3.08(s, 3H), 1.31(t, 2H), 1.32–1.25(t, *J*=7.0 Hz, 3H).

N-Benzyloxy-[5-(benzyloxyethoxycarbonylamino)pentyl]carbamic acid ethyl ester (2d)

Potassium carbonate (0.863 g, 6.25 mmol) was added to a solution of **1** (0.229 g, 1.25 mmol) and 1,5-dibromopentane (0.07 mL, 0.5 mmol) in dry acetonitrile (5 mL) at rt and the mixture was heated at reflux for two days. The reaction mixture was cooled and poured into water (50 mL), extracted with CH₂Cl₂ (3×20 mL). The combined organic layer was dried (Na₂SO₄) and the solvent was removed *in vacuo*. The crude product was purified by radial chromatography (EtOAc/hexanes) followed by a second purification by radial chromatography (CH₂Cl₂) to give **2c** (0.265 g, 89.5%) as colorless oil: IR (neat) 2981, 2938, 1704 cm⁻¹; ¹H NMR (200 MHz) δ 7.48–7.28(m, 10H), 4.83(s, 4H), 4.20(q, *J*=7.0 Hz, 4H), 3.41(t, *J*=7.0 Hz, 4H), 1.71–1.48(m, 4H), 1.38–1.22(m, 2H), 1.30(t, *J*=7.0 Hz, 6H); ¹³C NMR (50 MHz) δ 157.4, 135.6, 129.3, 128.5, 128.4, 77.1, 62.0, 49.6, 26.8, 23.9, 14.6. Anal. Calcd for C₂₅H₃₄N₂O₆: C, 65.48; H, 7.47; N, 6.11. Found: C, 65.29; H, 7.63; N, 5.87.

Representative procedure for the intermolecular acylation of 2a-c. Synthesis of 2-Benzenesulfonyl-N-benzyloxy-N-methyl acetamide (3a)

A solution of LHMDs (1.24 mL, 1.24 mmol) was added to a solution of methyl phenyl sulfone (0.097 g, 0.62 mmol) in anhydrous THF (2.5 mL) at –78°C under N₂ and the mixture was stirred at –78°C for 30 min. A solution of **2a** (0.130 g, 0.62 mmol) in anhydrous THF (2.5 mL) was added and the reaction mixture stirred at –78°C for 30 min and then at rt for 16 h. The reaction was quenched with 10% aqueous AcOH solution (5 mL) and the solvent was removed *in vacuo*. The residue was diluted with EtOAc (50 mL), washed with sat'd NaHCO₃ (2×10 mL), brine (10 mL) and dried (Na₂SO₄). The solvent was removed *in vacuo*. The crude product was purified by radial chromatography to give **3a** (0.144 g, 72.7%) as colorless oil: IR (neat) 3065, 3032, 2929, 1668 cm⁻¹; ¹H NMR (200 MHz) δ 8.04–7.85(m, 2H), 7.75–7.48(m, 3H), 7.48–7.30(m, 5H), 4.94(s, 2H), 4.22(s, 2H), 3.19(s, 3H); ¹³C NMR (100 MHz) δ 162.9, 139.3, 134.0, 133.8, 129.6, 129.3, 129.0, 128.9, 128.6, 76.8, 58.1, 33.6. Anal. Calcd for C₁₆H₁₇NO₄S: C, 60.17; H, 5.37; N, 4.39. Found: C, 60.37; H, 5.39; N, 4.43.

N-Benzyloxy-N-methylmalonamic acid tert-butyl ester (3e)

A solution of *t*-butyl acetate (0.216 g, 1.86 mmol) in anhydrous THF (2 mL) was added to a solution of LHMDs (1.86 mL, 1.86 mmol) in anhydrous THF (2 mL) at –78°C under nitrogen and the solution stirred at –78°C for 30 min. A solution of **2a** (0.195 g, 0.93 mmol) in anhydrous THF (2 mL) was then added and the reaction mixture stirred at –78°C for 4 h and then at rt for 16 h. The reaction work up followed the representative procedure. The product **3e** (0.195 g, 75.3%) was obtained as a colorless oil. IR (neat) 2934, 2979, 1732, 1668 cm⁻¹; ¹H NMR (200 MHz) δ 7.49–7.30(m, 5H), 4.86(s, 2H), 3.35(s, 2H), 3.23(s, 3H), 1.43 (s, 9H); ¹³C NMR (50 MHz) δ 168.6, 166.4, 134.3, 129.3, 129.0, 128.7, 81.6, 76.4, 41.8, 33.7, 27.9. Anal. Calcd for C₁₅H₂₁NO₄: C, 64.50; H, 7.58; N, 5.01. Found: C, 64.63; H, 7.50; N, 4.63.

2-Benzenesulfonyl-*N*-[5-(benzenesulfonylacetylbenzyloxyamino)pentyl-*N*-benzyloxy acetamide (3l)

Following the representative procedure using **2d** (0.229 g, 0.5 mmol), methyl phenylsulfone (0.172 g, 1.1 mmol) and LHMDs (2.0 mL, 2.0 mmol), the product **3l** (0.262 g, 77.3%) was obtained as a white solid. mp 197.0–198.0 °C; IR (KBr) 3009, 2930, 2877, 1659 cm⁻¹; ¹H NMR (200 MHz) δ 7.92–7.90(m, 4H), 7.64–7.51(m, 6H), 7.39(s, 10H), 4.90(s, 4H), 4.19(s, 4H), 3.60(t, *J*=7.0 Hz, 4H), 1.60–1.52(m, 4H), 1.26–1.22 (m, 2H); ¹³C NMR (50 MHz) δ 162.6, 139.6, 133.9, 129.5, 129.3, 129.0, 128.9, 128.6, 76.8, 58.3, 45.3, 26.2, 23.6. Anal. Calcd for C₃₅H₃₈N₂O₈S₂: C, 61.93; H, 5.64; N, 4.13. Found: C, 61.58; H, 5.39; N, 3.87.

2-Benzenesulfonylpent-4-enoic acid {5-[(2-benzenesulfonylpent-4-enoyl)benzyloxyamino]pentyl}benzyloxy amide (3m)

Following the representative procedure using **2d** (0.345 g, 0.75 mmol), (but-3-enylsulfonyl) benzene (0.323 g, 1.65 mmol), LHMDs (3.3 mL, 3.3 mmol) in THF (10 mL), the product **3m** (0.380 g, 66.8%) was obtained as a pale yellow oil. IR (neat) 3066, 3033, 2945, 2871, 1661, 1652 cm⁻¹; ¹H NMR (400 MHz) δ 7.87–7.84(m, 4H), 7.66–7.62(m, 6H), 7.49–7.38(m, 10H), 5.56–5.48(m, 2H), 5.07–4.98(m, 6H), 4.87–4.76(m, 4H), 3.74–3.67(m, 2H), 3.51–3.45(m, 2H), 2.70–2.66(m, 2H), 2.57–2.49(m, 2H), 1.53–1.47(m, 4H), 1.27–1.20(m, 2H); ¹³C NMR (100 MHz) δ 165.4, 136.8, 134.1, 133.9, 131.8, 129.9, 129.3, 129.1, 128.8, 128.7, 119.0, 77.4, 64.7, 45.5, 32.4, 26.0, 23.6. Anal. Calcd for C₄₁H₄₆N₂O₈S₂: C, 64.88; H, 6.11; N, 3.69. Found: C, 64.66; H, 6.19; N, 3.68.

N-Benzyloxy-2-{3,5-bis-[2-benzyloxymethylcarbamoyl]-2-*tert*-butoxycarbonyl ethyl}benzyl]-*N*-methylmalonic acid *tert*-butyl ester (4)

Potassium carbonate (0.690 g, 5.0 mmol) was added to a solution of **3e** (0.279 g, 1.01 mmol) and 1,3,5-tris(bromomethyl)benzene (0.120 g, 0.34 mmol) in dry acetonitrile (10 mL) at rt and the mixture was heated at reflux for 2 days. After cooling, the reaction mixture was poured into water (50 mL), extracted with CH₂Cl₂ (3×20 mL). The combined organic layer was dried (Na₂SO₄) and the solvent was removed *in vacuo*. The crude product was purified by radial chromatography to give **4** (0.232 g, 71.8%) as a colorless oil: IR (neat) 2979, 2933, 1732, 1668 cm⁻¹; ¹H NMR (200 MHz) δ 7.45–7.15(m, 15H), 6.88(d, *J*=2.9 Hz, 3H), 4.67–4.58(m, 6H), 3.93–3.70(m, 3H), 3.11–3.00(m, 15H), 1.34(s, 27H); ¹³C NMR (50 MHz) δ 170.8, 168.4, 139.0, 134.5, 129.2, 128.8, 128.6, 127.9, 81.5, 76.5, 51.4, 34.5, 34.3, 27.9. Anal. Calcd for C₅₄H₆₉N₃O₁₂•3H₂O: C, 64.46; H, 7.51; N, 4.18. Found: C, 64.23; H, 7.17; N, 4.12.

N-Benzyloxy-3-{3,5-bis-[2-benzyloxymethylcarbamoyl]ethyl}phenyl]-*N*-methyl propionamide (5)

Trifluoroacetic acid (0.08 mL, 0.92 mmol) was added to a solution of **4** (0.146 g, 0.15 mmol) in CH₂Cl₂ (1 mL) at 0 °C and the mixture was stirred at rt for 2 h. Solvent and the excess trifluoroacetic acid were removed *in vacuo*. The crude tricarboxylic acid was dissolved in toluene (5 mL) and the solution was heated at reflux for 2 d. The solvent was removed *in vacuo*. The crude product was purified by radial chromatography to give **5** (0.084 g, 85.7%) as a colorless oil: IR (neat) 3031, 2931, 1661 cm⁻¹; ¹H NMR (200 MHz) δ 7.38–7.26(m, 15H), 6.81(s, 3H), 4.73(s, 6H), 3.18(s, 9H), 2.96–2.73(m, 6H), 2.73–2.51(m, 6H); ¹³C NMR (50 MHz) δ 174.3, 141.6, 134.6, 129.2, 129.0, 128.7, 126.3, 76.3, 34.1, 33.8, 30.6. Anal. Calcd for C₃₉H₄₅N₃O₆: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.82; H, 7.09; N, 6.55.

3-{3,5-Bis-[2-hydroxymethylcarbamoyl]ethyl}phenyl]-*N*-hydroxyl-*N*-methyl propionamide (6)

Palladium on carbon (10%, 16 mg) was added to a solution of **5** (0.083 g, 0.127 mmol) in MeOH (4 mL) and the mixture was stirred at rt under H₂ atmosphere for 6 h. The catalyst was removed by centrifugation followed by filtration. After drying under high vacuum, the

trihydroxamic acid **6** (0.034 g, 70.8%) was obtained as a pale yellow oil: IR (neat) 3412, 2930, 1605 cm^{-1} ; ^1H NMR (200 MHz, CD_3OD) δ 6.92(s, 3H), 3.19(s, 9H), 2.84-2.73(m, 12H); ^{13}C NMR (50 MHz, CD_3OD) δ 173.6, 141.5, 125.8, 36.6, 32.7, 29.2. Anal. Calcd for $\text{C}_{18}\text{H}_{27}\text{N}_3\text{O}_6\cdot\text{H}_2\text{O}$: C, 54.12; H, 7.32; N, 10.52. Found: C, 54.36; H, 7.27; N, 10.43.

2-Benzenesulfonyl-*N*-[5-((2-benzenesulfonyl-4-[2-(3-benzyloxy-2-oxo-2*H*-pyridin-1-yl)ethoxy]butyryl)benzyloxyamino)pentyl]-*N*-benzyloxy-4-[2-(3-benzyloxy-2-oxo-2*H*-pyridin-1-yl)-ethoxy]butyramide (10)

To a solution of **31** (123 mg, 0.18 mmol) in dry acetonitrile (5 mL) at rt was added K_2CO_3 (248 mg, 1.8 mmol) and 3-(benzyloxy)-1-(2-(2-iodoethoxy)ethyl)pyridin-2(1*H*)-one, **13**,¹⁹ (176 mg, 0.44 mmol) and the mixture heated at reflux for 2 d. After cooling, the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (100 mL). The organic layer was dried (Na_2SO_4) and the solvent removed *in vacuo*. Purification by radial chromatography gave **10** (0.195 g, 88.6%) as a viscous yellow oil. IR (neat) 3065, 3031, 2871, 2931, 1660, 1652, 1606 cm^{-1} ; ^1H NMR (400 MHz) δ 7.94-7.78(m, 4H), 7.70-7.45(m, 6H), 7.45-7.27(m, 20H), 6.69-6.53(m, 4H), 5.86-5.77(m, 2H), 5.12-4.97(m, 4H), 4.97-4.80(m, 4H), 4.25-4.12(m, 2H), 4.07-3.92(m, 2H), 3.84-3.70(m, 2H), 3.68-3.48(m, 8H), 3.44-3.29(m, 2H), 3.24-3.11(m, 2H), 2.27-1.18(m, 10H); ^{13}C NMR (100 MHz) δ 165.7, 158.0, 148.7, 137.1, 136.4, 134.0, 130.2, 129.8, 129.6, 129.3, 128.9, 128.7, 128.5, 127.9, 127.3, 115.8, 104.0, 77.2, 70.7, 68.5, 67.3, 62.8, 49.5, 45.8, 45.0, 28.5, 26.3, 23.8.

***N*-Benzyloxy-*N*-[5-(benzyloxy-4-[2-(3-benzyloxy-2-oxo-2*H*-pyridin-1-yl)ethoxy]butyryl)benzyloxyamino)pentyl]-4-[2-(3-benzyloxy-2-oxo-2*H*-pyridin-1-yl)-ethoxy] butyramide (11)**

To a solution of **10** (0.122 g, 0.1 mmol) in MeOH (2 mL) at 0 °C was added Na_2HPO_4 (0.114 g, 0.8 mmol) and 10% Na/Hg amalgam (0.56 g, 2.4 mmol). The mixture was stirred at 0 °C for 5 h and then at rt for 16 h. The reaction mixture was vacuum filtered through a short silica gel column and rinsed with MeOH (50 mL). The solvent was removed *in vacuo*. The residue was diluted with EtOAc (50 mL), washed with sat'd NaHCO_3 (3×10 mL) and dried (Na_2SO_4). The solvent was removed *in vacuo*. Purification by radial chromatography gave the protected hydroxamic acid **11** (0.072 g, 76.6%) as colorless oil. IR (neat) 3064, 3033, 3937, 2868, 1652, 1602 cm^{-1} ; ^1H NMR (400 MHz) δ 7.45-7.27(m, 20H), 6.94(dd, $J=6.8$, 1.6 Hz, 2H), 6.59(dd, $J=7.4$, 1.6 Hz, 2H), 5.89(t, $J=7.2$ Hz, 2H), 5.07(s, 4H), 4.75(s, 4H), 4.11(t, $J=4.9$ Hz, 4H), 3.70(t, $J=5.1$ Hz, 4H), 3.64-3.55(m, 4H), 3.39(t, $J=6.2$ Hz, 4H), 2.41(t, $J=7.2$ Hz, 4H), 1.81(quintet, $J=6.4$ Hz, 4H), 1.62(quin, $J=7.6$ Hz, 4H), 1.31-1.21(m, 2H); ^{13}C NMR (100 MHz) δ 174.0, 158.1, 148.7, 136.4, 134.6, 130.5, 129.0, 128.9, 128.7, 128.5, 127.9, 127.3, 115.7, 103.9, 76.3, 70.7, 70.4, 68.5, 49.7, 45.4, 28.9, 26.6, 24.6, 24.0. Anal. Calcd for $\text{C}_{55}\text{H}_{64}\text{N}_4\text{O}_{10}$: C, 70.19; H, 6.85; N, 5.95. Found: C, 70.33; H, 6.55; N, 6.12.

***N*-Hydroxy-*N*-[5-(hydroxy-4-[2-(3-hydroxy-2-oxo-2*H*-pyridin-1-yl)ethoxy]butyryl)benzyloxyamino)pentyl]-4-[2-(3-hydroxy-2-oxo-2*H*-pyridin-1-yl)ethoxy] butyramide (12)**

Palladium on carbon (10%, 10 mg) was added to a solution of **11** (54 mg, 0.057 mmol) in MeOH (2 mL) and the mixture stirred at rt under H_2 atmosphere for 16 h. The catalyst was removed by centrifugation followed by filtration. The solvent was removed *in vacuo*. The dihydroxamic acid/dihydroxypyridinone **12** (30 mg, 90.9%) was obtained as a reddish oil. IR (neat) 3207(br), 2931, 2869, 1652, 1601 cm^{-1} ; ^1H NMR (300 MHz, CD_3OD) δ 7.10(d, $J=6.7$ Hz, 2H), 6.82(d, $J=7.4$ Hz, 2H), 6.20(t, $J=7.2$ Hz, 2H), 4.17(t, $J=5.0$ Hz, 4H), 3.70(t, $J=5.1$ Hz, 4H), 3.72(t, $J=4.7$ Hz, 4H), 3.56(t, $J=6.8$ Hz, 4H), 3.45(t, $J=6.2$ Hz, 4H), 2.48(t, $J=7.3$ Hz, 4H), 1.79(quintet, $J=6.2$ Hz, 4H), 1.64(quintet, $J=6.5$ Hz, 4H), 1.29(t, $J=6.8$ Hz, 2H); ^{13}C NMR (100 MHz, CD_3OD) δ 175.6, 160.0, 148.1, 130.4, 117.1, 107.6, 71.5, 69.4, 50.8, 48.7, 34.7, 30.0, 27.3, 26.0, 24.6. Anal. Calcd for $\text{C}_{27}\text{H}_{40}\text{N}_4\text{O}_{10}\cdot\text{H}_2\text{O}$: C, 54.17; H, 7.07; N, 9.36. Found: C, 53.95; H, 6.98; N, 9.04.

9,14-Bis-benzenesulfonyl-1,7-bis-benzyloxy-1,7-diazacyclopentadec-11-ene-8,15-dione (**14**)

To a solution of Grubbs' catalyst (2nd generation, 15 mg, 5% mmol) in CH₂Cl₂ (30 mL) at rt under N₂ was added a solution of **3m** (0.268 g, 0.35 mmol) in CH₂Cl₂ (10 mL) and the mixture was heated at reflux for 20 h. The solvent was removed *in vacuo*. The crude product was purified by radial chromatography (EtOAc:hexane=1:4~1:1) to give **14** as yellowish oil (0.217 g, 84.7%, mixture of diastereomers) Anal. Calcd for C₃₉H₄₂N₂O₈S₂: C, 64.09; H, 5.79; N, 3.83. Found: C, 64.06; H, 5.61; N, 3.52. In order to characterize and simplify the NMR spectra, **14** was purified by a second careful chromatography to give less polar isomer and more polar isomer. **Less polar isomer**: IR (neat) 3065, 2944, 1661, 1652 cm⁻¹; ¹H NMR (200 MHz) δ 7.89-7.74(m, 4H), 7.72-7.59(m, 2H), 7.59-7.44(m, 4H), 7.44-7.29(m, 10H), 5.14(t, *J*=3.0 Hz, 2H), 5.09(d, *J*=10.3 Hz, 2H), 4.89(d, *J*=10.2 Hz, 2H), 4.70(dd, *J*=11.8, 1.4 Hz, 2H), 4.19(ddd, *J*=14.6, 11.0, 3.6 Hz, 2H), 3.22(dt, *J*=14.6, 3.6 Hz, 2H), 2.59(d, *J*=13.2 Hz, 2H), 2.42-2.33(m, 2H), 1.81-1.74(m, 2H), 1.46-1.39(m, 2H), 1.14(quin, *J*=7.4 Hz, 2H); ¹³C NMR (50 MHz) δ 165.2, 136.9, 134.2, 134.0, 130.1, 129.0, 128.9, 128.8, 128.7, 127.8, 76.6, 64.9, 45.5, 31.2, 26.5, 23.6. **More polar isomer**: IR (neat) 3065, 2945, 1668 cm⁻¹; ¹H NMR (200 MHz) δ 7.91-7.74(m, 4H), 7.73-7.59(m, 2H), 7.58-7.44(m, 4H), 7.44-7.29(m, 10H), 5.19(d, *J*=5.9 Hz, 2H), 4.91(d, *J*=11.0 Hz, 2H), 4.88(d, *J*=10.2 Hz, 2H), 4.72(dd, *J*=9.5, 3.7 Hz, 2H), 4.16(ddd, *J*=14.6, 11.7, 2.2 Hz, 2H), 3.14(dt, *J*=14.6, 3.7 Hz, 2H), 2.52-2.41(m, 4H), 1.65-1.54(m, 2H), 1.34-1.25(m, 2H), 1.12-1.03(m, 2H); ¹³C NMR (50 MHz) δ 165.3, 136.8, 134.0, 133.9, 130.1, 129.2, 129.1, 128.9, 128.7, 127.5, 76.6, 65.6, 44.5, 27.6, 27.1, 24.6.

1,7-Bis-benzyloxy-1,7-diazacyclopentadec-11-ene-8,15-dione (**15**)

To a solution of **14** (0.539 g, 0.74 mmol) in MeOH (15 mL) at 0°C was added Na₂HPO₄ (0.838g, 5.9 mmol) and 10% Na/Hg amalgam (4.15 g, 17.7 mmol) and the mixture was stirred at 0°C for 4h and at rt overnight. The reaction mixture was vacuum filtered through a short silica gel column rinsing with MeOH (50 mL). The solvent was removed *in vacuo*. The residue was diluted with EtOAc (50 mL), washed with sat'd NaHCO₃ (3×10mL) and dried (Na₂SO₄). The solvent was removed *in vacuo*. Purification by radial chromatography gave **15** (0.235g, 70.8%) as a yellowish oil. IR (neat) 3064, 3032, 2932, 2860, 1661, 1652 cm⁻¹; ¹H NMR (200 MHz) δ 7.49-7.21(m, 10H), 5.61-5.35(m, 2H), 4.88-4.63(m, 4H), 3.89-3.52(m, 4H), 2.63-2.17(m, 8H), 1.75-1.42(m, 4H), 1.39-1.08(m, 2H); ¹³C NMR (50 MHz) δ 173.5, 134.9, 129.5, 129.0, 128.9, 128.6, 75.9, 75.8, 44.1, 32.4, 30.9, 26.9, 26.2, 23.6, 23.5. Anal. Calcd for C₂₇H₃₄N₂O₄: C, 71.97; H, 7.61; N, 6.22. Found: C, 71.88; H, 7.72; N, 6.19.

1,7-Dihydroxy-1,7-diazacyclopentadecane-8,15-dione (**16**)

Palladium on carbon (10%, 26 mg) was added to a solution of **15** (0.139 g, 0.31 mmol) in MeOH (6 mL) and the mixture was stirred at rt under H₂ atmosphere for 18 h. The catalyst was removed by centrifugation followed by filtration. The solvent was removed *in vacuo*. The macrocyclic dihydroxamic acid **16** (0.081 g, 96.4%) was obtained as a light pink solid, which was homogenous based on ¹H NMR and TLC. mp 195.0–196.0 °C; IR (KBr) 3195(br), 2941, 2864, 1587 cm⁻¹; ¹H NMR (200 MHz, CD₃OD) δ 3.87-3.44(m, 4H), 2.72-2.16(m, 4H), 1.91-1.46(m, 8H), 1.46-1.02(m, 6H); ¹³C NMR (50 MHz, CD₃OD) δ 176.3, 47.9, 31.9, 29.1, 26.8, 25.2, 23.7. Anal. Calcd for C₁₃H₂₄N₂O₄•0.25H₂O: C, 56.40; H, 8.92; N, 10.12. Found: C, 56.14; H, 9.05; N, 10.13.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by grants from the National Institutes of Health under PHS Grant no. S06 GM08136 and 1SC3GM084809-01.

† Portions of this work were presented at the 232nd American Chemical Society National Meeting, San Francisco, CA, September 10–14, 2006, ORGN 534.

References

1. a) Renshaw JC, Robson GD, Trinci APJ, Wiebe MG, Livens FR, Collison D, Taylor RJ. *Mycol. Res* 2002;106/10:1123–1142. b) Dhungana S, Miller MJ, Dong L, Ratledge C, Crumbliss AL. *J. Am. Chem. Soc* 2003;125:7654–7663. [PubMed: 12812507] c) Dhungana S, Ratledge C, Crumbliss AL. *Inorg. Chem* 2004;43:6274–6183. [PubMed: 15446873]
2. a) Tam TF, Leung-Toung R, Li W, Wang Y, Kariman K, Spino M. *Curr. Med. Chem* 2003;10:938–995. b) Kalinowski DS, Richardson DR. *Pharmacological Reviews* 2005;57:547–583. [PubMed: 16382108]
3. a) Buss JL, Torti FM, Torti SV. *Curr. Med. Chem* 2003;10:1021. [PubMed: 12678674] b) Lovejoy DB, Richardson DR. *Curr. Med. Chem* 2003;10:1035. [PubMed: 12678675] c) Weinberg ED. *Advances in Applied Microbiology* 2003;52:187–204. [PubMed: 12964245] d) Richardson DR. *Critical Reviews in Oncology and Hematology* 2002;42:267–281. e) Richardson DR. *Curr. Med. Chem* 2005;12:2711. [PubMed: 16305467] f) Weinberg ED. *Hemoglobin* 2008;32:117. [PubMed: 18274989]
4. a) Miller MJ, Zhao G, Vakulenko S, Franzblau S, Mollann U. *Org. Biomol. Chem* 2006;4:4178–4185. [PubMed: 17312974] b) Meyer D. *Curr. Pharm. Des* 2006;12:1943–1947. [PubMed: 16787239] c) Vergne AF, Walz AJ, Miller MJ. *Nat. Prod. Rep* 2000;17:99–116. [PubMed: 10714901] d) Miller MJ, Malouin F. *Acc. Chem. Res* 1993;26:241.
5. TACE inhibition a) Lu Z, Ott GR, Anand R, Liu R-Q, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos J, Duan JJ-W. *Bioorg. Med. Chem. Lett* 2008;18:1958–1962. [PubMed: 18282708] b) Ott GR, Azakawa N, Lu Z, Liu R-Q, Covington MB, Vaddi K, Qian M, Newton RC, Christ DD, Trzaskos JM, Decicco CP, Duan JJ-W. *Bioorg. Med. Chem. Lett* 2008;18:694–699. [PubMed: 18061445] Bacterial peptide deformylase inhibition: c) Jain R, Chen D, White RJ, Patel DV, Yuan Z. *Curr. Med. Chem* 2005;12:1607–1621. [PubMed: 16022661] PDE4 inhibition: d) Ochiai H, Ohtani T, Ishida A, Kusumi K, Kato M, Kohno H, Odagaki Y, Kishikawa K, Yamamoto S, Takeda H, Obata T, Nakai H, Toda M. *Bioorg. Med. Chem* 2004;12:4645–4665. [PubMed: 15358291] Carbonic anhydrase inhibition e) Ilies, MA.; Banciu, MD. *Carbonic Anhydrase Its Inhibitors and Activators*. CRC Press; 2004. Chapter 7
6. For recent reviews on histone deacetylase inhibitors see: a) Jones P, Steinkühler C. *Curr. Pharm. Design* 2008;14:545. b) Dokmanovic M, Clarke C, Marks PA. *Mol. Cancer Res* 2007;5:981. [PubMed: 17951399] c) Marks PA, Breslow R. *Nature Biotechnology* 2007;25:84. d) Xu WS, Parmigiani RB, Marks PA. *Oncogene* 2007;26:5541. [PubMed: 17694093] e) Monneret C. *Eur. J. Med. Chem* 2005;40:1. [PubMed: 15642405]
7. a) Hanessian S, Moitessier N, Gauchet C, Viau M. *J. Med. Chem* 2001;44:3066. [PubMed: 11543675] b) Woessner, JF.; Nagase, H. *Matrix Metalloproteinases and TIMPs*. Oxford: 2000. p. 109-125. c) Brown, P. *Matrix Metalloproteinases*. Parks, WC.; Mecham, RP., editors. Academic Press: San Diego; 1998. p. 243-262. d) Kumaran S, Gupta SP. *J. Enz. Inhib. Med. Chem* 2007;22(1):23. e) Skotnicki JS, DiGrandi MJ, Levin JI. *Curr. Opin. Drug Discovery and Development* 2003;6/5:742–759. f) Park S-K, Han SB, Lee K, Lee HJ, Kho YH, Chun H, Choi Y, Yang JY, Yoon YD, Lee C-W, Kim HM, Choi H-M, Tae HS, Lee H-Y, Nam K-Y, Han G. *Biochem. Biophys. Res. Commun* 2006;341:627–634. [PubMed: 16438938]
8. For reviews on the use of hydroxamic acids as pharmacological agents see: a) Muri EMF, Nieto MJ, Sindelar RD, Williamson JS. *Curr. Med. Chem* 2002;9:1631–1653. [PubMed: 12171558] b) Muri EMF, Nieto MJ, Williamson JS. *Med. Chem. Rev.-Online* 2004;1:385–394.
9. a) Koshti N, Gantla VR, Jacobs HK, Gopalan AS. *Synthetic Commun* 2002;32/24:3779–3790. b) Bisset W, Jacobs H, Koshti N, Stark P, Gopalan A. *Reactive and Functional Polymers* 2003;55/2:109–119. c) Koshti NM, Jacobs HK, Martin PA, Smith PH, Gopalan AS. *Tetrahedron Lett* 1994:5157–5160.

10. Sandler, SR.; Karo, W. Organic Functional Group Preparations. Vol. 2nd edn.. Vol. vol. 3. San Diego: Academic Press; 1989. p. 482-522.
11. For some syntheses of hydroxamic acids see: a) Sibi MP, Hasegawa H, Ghorpade SR. Org. Lett 2002;4:3343–3346. [PubMed: 12323014] b) Sibi MP, Hasegawa H. Org. Lett 2002;4:3347–3349. [PubMed: 12323015] c) Hu J, Miller MJ. J. Org. Chem 1994;59:4858–4861.
12. For a review see: a) Yang K, Lou B. Mini Rev. Med. Chem 2003;3:349–360. [PubMed: 12678828] For recent papers not cited in the above review see: b) Volonterio A, Bravo P, Zanda M. Tetrahedron Lett 2001;42:3141–3144. c) Krchnák V, Slough GA. Tetrahedron Lett 2004;45:4649–4652. d) Yin Z, Low K, Lye P. Synth. Commun 2005;35:2945–2950. e) Porcheddu A, Giacomelli G. J. Org. Chem 2006;71:7057–7059. [PubMed: 16930063]
13. Massaro A, Mordini A, Reginato G, Russo F, Taddei M. Synthesis 2007:3201.
14. White JD, Blakemore PR, Milicevic S, Choudhry SC, Cupano J, Serico L. Org. Lett 2002;4:1803–1806. [PubMed: 12000303]
15. Hernandez NM, Sedano MJ, Jacobs HK, Gopalan AS. Tetrahedron Lett 2003;44:4035–4039.
16. Nahm S, Weinreb SM. Tetrahedron Lett 1981;22:3815–3818.
17. Lithium *t*-butyl acetate was generated by slow addition of *t*-butyl acetate to a solution of LHMDs in THF at –78°C to avoid or reduce the self-condensation of *t*-butyl acetate.
18. Our preliminary binding studies show that when trihydroxamate **6** is mixed with an equimolar quantity of Fe(III) in PIPES buffer at pH 7.4, a trishydroxamate **6**-Fe(III) complex ($\lambda_{\text{max}} = 430\text{nm}$) is formed.
19. Lambert TN, Dasaradhi L, Huber VJ, Gopalan AS. J. Org. Chem 1999;64:6097.
20. Gorden AEV, Xu J, Raymond KN. Chem. Rev 2003;103:4207–4282. [PubMed: 14611263]
21. Steinman DH, Curtin ML, Garland RB, Davidsen SK, Heyman HR, Holms JH, Albert DH, Magoc TJ, Nagy IB, Marcotte PA, Li J, Morgan DW, Hutchins C, Summers JB. Bioorg. Med. Chem. Lett 1998;8:2087–2092. [PubMed: 9873491]
22. Xue C-B, Voss ME, Nelson DJ, Duan JJ-W, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGrado WF, Hardman KD, Teleha CA, Jaffee BD, Liu R-Q, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP. J. Med. Chem 2001;44:2636–2660. [PubMed: 11472217]
23. Inglesi M, Nicola M, Magnetti S. Farmaco 1990;45(12):1327–1340. [PubMed: 2090142]

Figure 1.
Strategy for the synthesis of hydroxamic acids

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 5.

Table 1

Results for the acylation of **2a–d** with carbon nucleophiles

$\text{R}'\text{CH}_2\text{EWG} \xrightarrow[2. \text{ 2, } -78^\circ\text{C to rt}]{1. \text{ LHMDs, THF, } -78^\circ\text{C}} \text{BnO}-\text{N}(\text{R})-\text{C}(=\text{O})-\text{CH}(\text{R}')-\text{EWG}$		
Carbamate	R'CH ₂ EWG	Product
2a	CH ₃ SO ₂ Ph	3a
2a	CH ₃ SOPh	3b
2a	CH ₃ P(O)(OEt) ₂	3c
2a	CH ₃ SO ₂ N(CH ₃) ₂	3d
2a	CH ₃ CO ₂ ^t Bu	3e
2a	CH ₃ CN	3f
2a	CH ₃ CH ₂ SO ₂ Ph	3g

Carbamate	R'CH ₂ EWG	Product
2a		
2a 2b	$\text{CH}_3\text{CH}_2\text{CO}_2^t\text{Bu}$ $\text{CH}_3\text{CO}_2^t\text{Bu}$	
2c	$\text{CH}_3\text{CO}_2^t\text{Bu}$	
2d	$\text{CH}_3\text{CO}_2^t\text{Bu}$	
2d	$\text{CH}_3\text{SO}_2\text{Ph}$	
2d		

Conditions: a) Carbamate (1 eq), RCH₂EWG (1–1.1 eq), LHMDs (2 eq), THF, –78°C to rt.

b) carbamate (1 eq), RCH₂EWG (2 eq), LHMDs (2 eq), THF, –78°C to rt.

c) carbamate (1 eq), RCH₂EWG (4 eq), LHMDs (4 eq), THF, –78°C to rt.

d) carbamate (1 eq), RCH₂EWG (2.2 eq), LHMDs (4 eq), THF, –78°C to rt.